Association of Proton Pump Inhibitor (PPI) Use with Energy Intake, Physical Activity, and Weight Gain

Czwornog, Jennifer; Austin, Gregory L.

doi:10.3390/nu7105416

Cited by 21 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the BMI covariate was found to be associated with both suicidal ideation and depression. However, studies have shown that PPIs may cause weight gain 60 , therefore the BMI may not be truly independent of the exposure variable in this study.…”

Section: Discussionmentioning

confidence: 77%

Association of suicidal ideation and depression with the use of proton pump inhibitors in adults: a cross-sectional study

Fong

Chan²,

Lei³

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) were found to be associated with depression. This study aimed to find the cross-sectional association between recent PPI use and suicidal ideation. Item 9 of Patient Health Questionnaire-9 (PHQ-9) of the US National Health and Nutrition Examination Survey (NHANES) between 2005 and 2018 was used to categorize whether or not the participants had suicidal ideation. The secondary outcome of this study was depression and the scores of the PHQ-9 were used as the depression diagnostic instrument. The study population included 16,881 participants who were over 20 years old. The bivariate Rao-Scott χ2 test showed a significant association between PPI use and suicidal ideation (P < 0.001) and a stronger association was observed between PPIs and depression (P < 0.001). Multiple logistic regression analysis of the education, gender, race and age-adjusted model revealed that the PPI users had a 2.34 (95% CI 1.66–3.31) greater risk of having suicidal ideation than the non-PPI users. Middle-aged participants (40–49 years) showed the greatest number of differences in suicidal ideation between PPI and non-PPI users (P < 0.001). Future research should continue to consider the psychiatric effects of taking PPIs.

show abstract

Section: Discussionmentioning

confidence: 77%

Association of suicidal ideation and depression with the use of proton pump inhibitors in adults: a cross-sectional study

Fong

Chan²,

Lei³

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…144 Several studies have also revealed an association between PPIs and weight gain. 28,145,146 This effect on metabolism may be interpreted by the following mechanisms. The intestinal microbiota plays a central role based on the evidence that obesity in mice was shifted after transfer of gut microbiota from obese mice to germ-free mice.…”

Section: Ppi and Metabolic Riskmentioning

confidence: 99%

“…In a study prospectively enrolling 301 patients with celiac disease, exposure to PPIs independently increased the risk of metabolic syndrome and hepatic steatosis after 1 year of a gluten‐free diet (OR 22.9, P < 0.001) 144 . Several studies have also revealed an association between PPIs and weight gain 28,145,146 . This effect on metabolism may be interpreted by the following mechanisms.…”

Section: Ppi and Metabolic Riskmentioning

confidence: 99%

The impact of proton pump inhibitors in liver diseases and the effects on the liver

Liu

Chen

2022

J of Digest Diseases

View full text Add to dashboard Cite

In this systematic and comprehensive overview, we aimed to evaluate the impact of proton pump inhibitors (PPIs) on chronic liver diseases, especially on cirrhosis. A manual and comprehensive search of the PubMed database was conducted to obtain relevant literatures. PPIs altered the composition and function of the intestinal microflora and might lead to small intestinal bacterial overgrowth and bacterial translocation, which were associated with adverse effects in liver diseases. They might increase the risk of hepatic encephalopathy, spontaneous bacterial peritonitis, infections, and are related to an increased mortality in cirrhosis. PPIs might lead to an increased risk of hepatocellular carcinoma, although the mechanism is unknown, and the results are controversial. PPIs also had an impact on the direct‐acting antiviral regimen in patients with chronic hepatitis C. They were associated with an increased risk of liver abscess and increased mortality. Additionally, PPIs might lead to metabolic risk events, such as liver steatosis and weight gain. PPIs are associated with several adverse outcomes in liver diseases. Cautious use of PPIs is recommended and clinicians should be aware of the indications for their use in patients with liver diseases.

show abstract

“…Proton pump inhibitors (PPI) and histamine H2 receptor antagonists are groups of medications whose main action is a pronounced and long‐lasting reduction of gastric acid secretion. Interestingly, PPI use has been reported to be associated with a significant weight gain in men, while energy intake, physical activity and sedentary behaviour were unchanged (Czwornog & Austin, 2015; Yoshikawa, Nagato, Yamasaki, Kume, & Otsuki, 2009). Furthermore, it has been demonstrated that children prescribed with PPIs and H2 receptor antagonists were slightly more likely to develop obesity, with increasing manifestation depending on medication duration (Stark, Susi, Emerick, & Nylund, 2019).…”

Section: Manipulating Meal‐associated Brown Fat Thermogenesis To Achieve Weight Lossmentioning

confidence: 99%

The gut hormone secretin triggers a gut–brown fat–brain axis in the control of food intake

Schnabl

Klingenspor

2020

Experimental Physiology

View full text Add to dashboard Cite

Brown fat research concentrates on the energy expenditure function of this heating organ, whereas previous evidence for a role of brown fat in regulating energy intake has been mostly neglected. Ingestion of a single mixed meal activates human brown fat thermogenesis to the same degree as cold. In mice, activation of brown fat thermogenesis with a 3-adrenergic receptor agonist inhibits food intake. Pharmacological-blockade, however, inhibits neither mealassociated thermogenesis nor food intake. We recently identified the gut hormone secretin as a non-adrenergic activator of brown fat. In vivo, secretin treatment acutely increases energy expenditure and inhibits food intake in wild-type, but not in uncoupling protein 1 (UCP1)knockout (KO) mice, which lack thermogenic brown fat function. Concurrently, secretin alters gene expression of melanocortinergic peptides of hypothalamic neurons in wild-type mice, but not UCP1-KO. Blocking endogenous secretin with a neutralizing antibody attenuates brown fat thermogenesis during refeeding, increases food intake of mice, and alters ad libitum feeding behaviour. Taken together, these findings demonstrate that secretin triggers an endocrine gutbrown adipose tissue-brain axis in the control of satiation. We hypothesize that meal-associated activation of brown adipose tissue thermogenesis induced by secretin results in a rise in brain temperature and increased melanocortinergic signalling. Taken together, brown fat is not a mere heating organ dissipating excess calories but also involved in gut-brain communication in the control of food intake.

show abstract

Association of Proton Pump Inhibitor (PPI) Use with Energy Intake, Physical Activity, and Weight Gain

Cited by 21 publications

References 17 publications

Association of suicidal ideation and depression with the use of proton pump inhibitors in adults: a cross-sectional study

Association of suicidal ideation and depression with the use of proton pump inhibitors in adults: a cross-sectional study

The impact of proton pump inhibitors in liver diseases and the effects on the liver

The gut hormone secretin triggers a gut–brown fat–brain axis in the control of food intake

Contact Info

Product

Resources

About